Rezolute, Inc. (NASDAQ:RZLT) Receives Average Rating of “Hold” from Brokerages

Rezolute, Inc. (NASDAQ:RZLT) has been assigned an average recommendation of “Hold” from the eleven brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $8.75.

RZLT has been the topic of a number of research reports. Wedbush raised shares of Rezolute from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $2.00 to $5.00 in a research note on Wednesday, March 25th. Maxim Group lifted their price target on shares of Rezolute from $4.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen raised shares of Rezolute from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rezolute in a research note on Tuesday, April 21st.

Rezolute News Roundup

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright raised its Q1 2027 EPS estimate, indicating a somewhat better outlook for that quarter. Rezolute analyst estimate update
• Positive Sentiment: The firm also increased its Q2 2027 EPS estimate, another modest improvement in the near-term earnings view. Rezolute analyst estimate update
• Positive Sentiment: HC Wainwright lifted its FY2027 EPS forecast, implying better expected profitability over the medium term. Rezolute analyst estimate update
• Neutral Sentiment: The analyst also updated FY2028 and FY2029/FY2030 estimates, reflecting a broader refresh of the company’s longer-term model. Rezolute analyst estimate update
• Negative Sentiment: HC Wainwright cut its Q4 2026 EPS estimate, signaling weaker expected results in the next reported period. Rezolute analyst estimate update
• Negative Sentiment: The firm lowered its Q3 2027 and Q4 2027 EPS estimates, which may have contributed to the stock moving lower. Rezolute analyst estimate update
• Negative Sentiment: HC Wainwright also reduced its FY2026, FY2028, FY2029, and FY2030 EPS forecasts, pointing to slower anticipated earnings improvement over time. Rezolute analyst estimate update

Rezolute Price Performance

Rezolute stock opened at $3.34 on Monday. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46. The company’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $4.54. The firm has a market capitalization of $321.61 million, a price-to-earnings ratio of -4.07 and a beta of 0.66.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. As a group, analysts predict that Rezolute will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RZLT. RA Capital Management L.P. bought a new position in Rezolute in the fourth quarter valued at approximately $21,665,000. Opaleye Management Inc. lifted its position in shares of Rezolute by 595.9% in the fourth quarter. Opaleye Management Inc. now owns 6,287,156 shares of the company’s stock worth $14,838,000 after purchasing an additional 5,383,714 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Rezolute in the first quarter worth $10,489,000. Siren L.L.C. bought a new stake in shares of Rezolute in the first quarter worth $10,151,000. Finally, Balyasny Asset Management L.P. lifted its position in shares of Rezolute by 147.3% in the fourth quarter. Balyasny Asset Management L.P. now owns 4,506,861 shares of the company’s stock worth $10,636,000 after purchasing an additional 2,684,133 shares in the last quarter. Institutional investors own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.